Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 21;13:818522. doi: 10.3389/fneur.2022.818522

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ling, Chen, He, Feng, Weng, Cheng, Rong and Xie.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Head-to-head comparisons for secondary outcomes of drugs and placebo. (A) Pain relief more than 8 weeks (8 drugs). (B) Mental or sleep-related symptom relief (8 drugs). (C) Serious adverse events (11 drugs). Drugs are reported in efficacy and safety order sorted from top left to bottom right. Data are SMDs (95% CrI) and ORs (95% CrI) in the column-defining treatment compared with the row-defining treatment. For A and B, SMDs lower than 0 favor the column-defining treatment. For C, ORs lower than 1 favor near the top left one. Significant results are in bold. SMD, standard mean deviation; OR, odds ratio; CrI, credible interval; BTXA, botulinum toxin-A.